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ABSTRACT
The intestinal absorption of analgesic peptides (leucine enkephalin and kyotorphin) and modified peptides
in rat were studied. Although these peptides were not absorbed, the absorbability (absorption clearance)
of
these peptides were increased in the presence of peptidase inhibitors. In order to kinetically analyze these
phenomena, we proposed the metabolic inhibition model, which incorporated the metabolic clearance
(metabolizability) with the absorption clearance. Metabolic activity was determined with intestinal
homogenates.  The higher the metabolic clearance was, the lower was the absorption clearance. The
relationships between the absorption clearance and the metabolic clearance of the experimental data as well
as of the theoretical values were hyperbolic. This model predicted the maximum absorption clearances of
cellobiose-coupled leucine enkephalin (0.654 l/min/cm) and kyotorphin (0.247 l/min/cm). Details of the
experimental methods are described. 
INTRODUCTION
The small intestine is the organ for nutrient absorption, which consists of digestion/metabolism and
transport. Although the digestion/metabolism of dietary protein or peptides or oligo- or polysaccharides
is required for absorption, medicinal drugs must be transported to systemic circulation without metabolic
degradation to perform their pharmacological action. Membrane transportability is also expected to be low,
since these compounds are hydrophilic and their molecular sizes are large. Therefore, the estimation of each
process (metabolism and transport) is required for the evaluation of intestinal absorption. For the kinetic
analysis of intestinal absorption, we proposed the metabolic inhibition model (1, 2),  which can evaluate
the intestinal absorption of analgesic peptides, leucine enkephalin (Tyr-Gly-Gly-Phe-Leu, LE) and
kyotorphin (L-tyrosyl-L-arginine, KTP). In this report, we summarize the experimental and analytical
procedures for the evaluation of intestinal absorption based on the metabolic inhibition model. KTP is an
endogenous compound, which releases methionine enkephalin, possessing analgesic activity (3), from the
striatum (4), and is hydrolyzed by peptidases such as aminopeptidase (5-8). Leucine enkephalin (LE), an
opioid peptide, is easily degraded to destyrosyl LE by aminopeptidase in the intestine (9,10). Thereby, we
clarified the rate-limiting process in the peptide absorption, and predicted the absorbability to discuss the
oral delivery of KTP.T.  Mizuma et al. 33
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Figure 1: Metabolic inhibition model for intestinal absorption of
drug.  Ci, Cs and Cm are the drug concentrations in the intestinal
tissue, on the serosal side and on the mucosal side, respectively.
CLm-i, CLi-m and CLi-s are the transport clearances from the
mucosal side into the intestinal tissue, and from the intestinal tissue
to the mucosal side and from the intestinal tissue to the serosal side,
respectively.  LCmet,int is the intrinsic clearance of metabolism by
peptidase in the intestinal tissue.  Ra is a remaining activity in the
intestinal tissue in the presence of peptidase inhibitors.
THEORY AND EXPERIMENT
Metabolic inhibition model
Kinetic analysis of the correlation between absorption clearance and metabolic clearance were performed
based on Eq. 1 according to the metabolic inhibition model for absorption (1,2) shown in Figure 1.
,where CLovt is overall transport clearance of peptide from the mucosal (1)
to the serosal sides, where no metabolic degradation of peptide in intestinal tissue occurs during absorption
process. This value means the maximum of the absorbability and is defined as
.  Here, CLm-i, CLi-m and CLi-s were transport clearances of peptide from (2)
the mucosal side to the intestinal tissue, from the intestinal tissue to the mucosal side, from the intestinal
tissue to the serosal side, respectively. RCmet is the ratio of clearances expressed by Eq. 3.
.  (3)
Ra, which is the remaining activity of
the metabolism in intestinal tissue, is
obtained by dividing CLmet in the
presence of peptidase inhibitor with
CLmet in its absence. CLmet,int is the
intrinsic clearance of metabolism in
intestinal tissue, and is CLmet in the
absence of any inhibitors. The
theoretical relationship between the
absorption clearance and the metabolic
clearance according to Eq. 1 is shown
in Fig. 2.  The hybrid parameters,
CLovt and RCmet, are obtained by
fitting data to Eq. 1, using a nonlinear
least squares fitting program, MULTI
(11).  The effect of complete inhibition
of peptidase activity on absorption rate
(Ei), which is defined by dividing
CLovt with the CLabs in the absence of
inhibitors, is expressed by Eq.4. 
(4)T.  Mizuma et al. 34
Biological Procedures Online • Vol.  1 No. 1 • May 14, 1998 • www.science.uwaterloo.ca/bpo
Estimation of absorption clearance
Absorption clearance, CLabs, was calculated by Eq.
5, which is the integrated form of Eq. 6 based on
definition.
(5)
Xabs is the amount of peptide absorbed from the
mucosal to the serosal sides for the time from 0 to T.
(6)
Vabs and Cmuc represent the absorption rate and
mucosal concentration respectively. Xabs and
AUCmuc represent the amount of drug absorbed to
the serosal side and the area under the curve of
peptide concentration on the mucosal side respectively. AUCmuc was calculated by the trapezoidal rule
(12).
Estimation of metabolic clearance and/or remaining activity of metabolic enzyme
The remaining activity (Ra) was calculated by Eq. 7, when the metabolism follows first-order kinetics (1).
, where kmet is rate constant of metabolism, and kmet,inhi and kmet,cont are kmet (7)
in the presence of peptidase inhibitor and kmet of control, respectively.  Kmet is calculated using
Chom = Co exp(- kmet × t)  (8). T, Co and Chom represent t and the concentrations at time 0 and t,
respectively. The kmet is calculated by fitting data to Eq. 8 using MULTI.
Ra is also calculated as follows (2):  , considering that  (9)
, and  , where CLmet,inhi and (10) (11)
CLmet,cont are CLmet in the presence of peptidase inhibitors and CLmet of control, respectively. Xmet
is the amount metabolized per one gram of wet weight of intestine in intestinal homogenate, and is
calculated by Eq. 5. AUChom, 0-T is the area under the concentration curve of peptide in the reaction mixture
for the time from 0 to T, and is calculated by the trapezoidal rule. Ww is wet weight per length of everted
intestine (g/cm). CT and C0 are peptide concentrations in the reaction mixture at time T and 0, respectively.
H is the concentration of homogenate (%, W/V) of the reaction mixture.T.  Mizuma et al. 35
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Estimation of elimination clearance from luminal side
Elimination clearance (CLeli) from the mucosal side was obtained by fitting the data to Eq. 12 using the
nonlinear least squares fitting program MULTI when the elimination from the mucosal side follows first-
order kinetics (1).
, where t, Co and Vmuc represent the time, the mucosal side (12)
concentration at time 0 and the medium volume in the mucosal side, respectively. 
CLeli was also calculated by Eq. 13 (2):  . Xeli is the amount eliminated from (13)
the mucosal side, and is calculated by  Xeli  = (CT - C0) x Vmuc (14). AUCmuc,0-T is the area under the
concentration curve of peptide on the mucosal side from the time 0 to T, and is calculated by the
trapezoidal rule (12). C T and C0 are peptide concentration on the mucosal side at time T and 0, respectively.
MATERIALS AND METHODS
Leucine enkephalin (LE), gentiobiose, kyotorphin (KTP) and L-tyrosyl-D-arginine ([D-Arg
2]kyotorphin,
D-KTP) were purchased from Sigma Chemical Co. (St. Louis, MO, USA). Cellobiose and Sephadex G-25
superfine were purchased from Nacalai Tesque (Kyoto, Japan) and Pharmacia LKB Biotechnology (Tokyo,
Japan), respectively. Ng-nitro-L-arginine benzyl ester (Arg(NO2)-OBzyl) tosylate and N, N'-
dicyclohexylcarbodiimide (DCC) were from Peptide Institute, Inc. (Osaka, Japan). N-t-Butyloxycarbonyl-
L-tyrosine (Boc-Tyr) was from Wako Pure Chemical Industries. (Osaka, Japan). L-Arginyl-L-tyrosine
(retro-isomer of KTP, Ret-KTP) was purchased from Bachem Feinchemikalien AG (Switzerland).
Synthesis of Cellobiose-coupled LE (CcpLE).  CcpLE was synthesized according to the method reported
in the previous study (13), which basically followed Gray's method (14). Briefly, LE, cellobiose and
sodium borohydride (1:10:10 mole ratio) dissolved in purified water were incubated at 37ºC for 3 to 4
weeks. The reaction mixture was concentrated by evaporation at 40ºC under reduced pressure. The resultant
solution was applied to Sephadex G-25 superfine column (55 mm I.D., 75 cm length) and eluted with water
at a flow rate of 3.5 ml/min. Each fraction eluted was checked by the HPLC under the conditions described
below. The fractionated solution containing CcpLE was concentrated by evaporation described above, and
was freeze-dried. The crude CcpLE dissolved in the mobile phase (25% acetonitrile, 2% methanol, 1.5%
acetic acid in water) was applied to a preparative ODS column (30 mm I.D., 30 cm length), and eluted with
the same mobile phase at a flow rate of 2.5 ml/min. Finally, the purified CcpLE was obtained by freeze-
drying after evaporation of methanol. CcpLE was confirmed by molecular ion peaks [M+H]
+ at 882.8 (m/z)
and [M+Na]
+ at 904.7 by electrospray ionization (ESI) method. Furthermore, the ninhydrin reaction of
CcpLE was negative, indicating that the amino group of LE was reacted with sugar. Sugar moiety was
confirmed by the phenol sulfuric reaction. T.  Mizuma et al. 36
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Synthesis of N-t-butyloxycarbonyl-L-kyotorphin (Boc-KTP).  Boc-KTP was synthesized from Boc-Tyr
and Arg(NO2)-OBzyl by the standard DCC method of peptide synthesis as follows. Boc-Tyr (1.055g) and
Arg(NO2)-OBzl (1.974g) were dissolved in the mixture of DMF (8 ml) and triethanolamine (580 l) by
stirring for 30 min at room temperature. DCC (890 mg) dissolved in ethylacetate was added to the solution
kept at 0ºC on ice by dropwise, and was stirred for 2 hr, and then further stirring of reaction mixture was
performed at room temperature under light-protection for 46 hr. The formation of Boc-Tyr-Arg(NO 2)-
OBzyl was confirmed by TLC and HPLC according to the method described below. The reaction mixture
was filtrated through paper filter. The resultant filtrate was concentrated by evaporation at 40ºC under
reduced pressure. The residue was dissolved in 10 ml of ethylacetate, and byproduct was removed by
extraction with water. The extraction was performed 3 times. Ethylacetate fraction was evaporated, and
crude Boc-Tyr-Arg(NO 2)-OBzyl was obtained. Boc-Tyr-Arg(NO 2)-OBzyl was dissolved in the mobile
phase (45% acetonitrile, 1.5% acetic acid) for the following liquid chromatography, and was applied to a
preparative liquid chromatography column (ODS, 30-50 m particle size, 30 mm id., 30 cm length, GL
Science, Tokyo, Japan). Each fraction (10 ml) eluted at a flow rate of 2.5 ml/min was collected to a tube.
Boc-Tyr-Arg(NO2)-OBzyl contained in fractions which was confirmed by HPLC assay, was evaporated.
Boc-Tyr-Arg(NO2)-OBzyl was dissolved in methanol (5 ml) in a flask, which was filled with nitrogen gas.
Into the solution, Pd-C was added, and the flask was filled with hydrogen gas. The solution was stirred for
1 day under light-protection at room temperature. After confirming deprotection of NO2 group by HPLC
or TLC assay, the solution was filtrated through celite on glass fiber sheet. The filtrate was evaporated. The
crude Boc-KTP was dissolved in the mobile phase, and was applied to the semipreparative column (TSKgel
ODS-80TM, 7.8 mm i.d., 30 cm length, Tosoh, Tokyo, Japan). The flow rate of mobile phase (20%
acetonitrile, 1.5% acetic acid in water) was 3.0 ml/min. The fractions containing Boc-KTP were collected,
and evaporated. Purified Boc-KTP was recrystalized with a mixture of ethylacetate and hexane.
Identification of Boc-KTP was performed by ESI mass spectrum showing molecular ion peaks[M+H]+ at
438.3 (m/Z) and [M+Na]+ at 460.3. The ninhydrin reaction was negative, but after hydrochloric acid
treatment it was positive, indicating the presence of Boc moiety at amino group of Tyr in the synthesized
Boc-KTP.
TLC. Sample was spotted on the TLC plate (6 cm x 5 cm), and developed with the solvent mixture of n-
butanol, methanol, water and acetic acid (10:8:2:1). After UV-detectable ( l=253.7nm) spot was checked,
the ninhydrin reagent was sprayed upon the TLC plate. After the TLC plate was heated, the spot was
checked. As another procedure, before the ninhydrin reagent was sprayed, diluted perchloric acid was
sprayed upon the plate, and the plate was heated.
HPLC. ODS-80TM column (6 mm i.d., 15 cm length) and mobile phase consisted of 30% acetonitrile,
0.05% phosphoric acid were used. The UV detector was set at 274 nm. The assay condition other than these
were described below.
Intestinal absorption. Intestinal absorption of peptides were performed with the everted small intestine
(15). Male Wistar rats (180-230g, JAPAN SLC. Inc., Japan) fasted overnight were anesthetized with ether,
and the intestinal blood was removed by saline perfusion. The jejunum was removed and everted. The
everted small intestine of 10 cm was placed in 30 ml of incubation medium (113.3 mM NaCl, 4.83 mM
KCl, 1.214 mM KH 2PO4, 1.205 mM MgSO 4, 16.96 mM NaHCO 3, 10.18 mM Na 2HPO4, 0.645 mM CaCl2,
pH 7.4) containing peptide at 250 M in a beaker at 37ºC. The serosal side was filled with 5 ml of theT.  Mizuma et al. 37
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incubation medium without peptides. When necessary, peptidase inhibitors were added to the medium.
Incubation media (100  l) were sampled from both the serosal and the mucosal sides at every 10 min until
60 min. The samples of CcpLE absorption experiment were mixed with 100  l of 10% perchloric acid
containing 12.5 mM L-phenylalanine as an internal standard of CcpTGG and 25 mM sodium 1-
naphthalenesulfonate as an internal standard of CcpLE for HPLC assay. The samples of the absorption
experiments of KTP, D-KTP and Boc-KTP were mixed with 100  l of internal standard solution (200  M
tryptophan in 10% perchloric acid for KTP, D-KTP and Ret-KTP, or 100  M Sodium 1-
naphthalensulfonate in acetonitrile for Boc-KTP) for the following HPLC assay. The mixture was
centrifuged at 11,000 x g for 5 min by a benchtop centrifuge KM-15200 (KUBOTA, Japan). Twenty-five
microliter of the resultant supernatant was applied to HPLC. The absorption experiment of phenol red (PR,
1 mM) was performed by the same method.
Metabolism in intestinal homogenates.  Ten cm of intestine was isolated according to the method
described in the intestinal absorption experiment, and was homogenized by Physcotron homogenizer
(Nichion Irika, Tokyo, Japan) in the same buffer as in the absorption experiment to prepare 10% intestinal
homogenate (W/V). Metabolic reaction was started by mixing 500  M peptide solution (0.6 ml) with
homogenate (0.5-2.5%) (0.6 ml) after preincubation for 5 min at 37 ºC. The reaction mixture was
periodically sampled. The procedure for the peptide assay was the same as in the absorption experiment.
Assay of LE, cellobiose-coupled LE (CcpLE) and its metabolites.  LE, CcpLE and its metabolite
(cellobiose-coupled tyrosylglycylglycine, CcpTGG) were determined by reversed-phase HPLC. For the
assay of LE and CcpLE, an octyl column (TSKgel OCTYL-80Ts, 4.6 mm I.D., 15 cm length, Tosoh Corp.,
Japan) and the mobile phase composed of 18% acetonitrile, 3% methanol and 0.05% phosphoric acid were
used. UV detector (274 nm) and fluorescence detector (Ex 278nm, Em 305nm) were used for the
purification and the transport experiments, respectively. For the assay of CcpTGG, HPLC condition
followed the previous method (13).
Assay of phenol red (PR).  Incubation media (100 ml) sampled from the serosal side and the mucosal side,
were mixed with 2.6 ml of 1 N sodium hydroxide. PR in the solution was determined by dual wavelength
spectrophotometry (l1: 610 nm, l2: 560 nm) using Spectrophotometer 557 (Hitachi, Japan).
Assay of KTP, Boc-KTP and their metabolites. KTP, Boc-KTP and their metabolites were determined
by reversed-phase HPLC. The HPLC system was consisted of a pump (Twincle, Jusco Co, Tokyo, Japan),
a UV detector (Shimadzu, Kyoto, Japan), a fluorescence detector (821-FP, Jasco) and an integrator (D-
2500, Hitachi Ltd, Tokyo, Japan). For the assay of KTP, D-KTP and Ret-KTP, the mobile phase composed
of 7% methanol and 0.05% phosphoric acid in pure water and an ODS column (80TM, 6 mm i.d., 15 cm
length, Tosoh Corp., Japan) were used. For the assay of Boc-KTP, the mobile phase composed of 20%
acetonitrile and 0.05% phosphoric acid in water and an ODS column (A-312, 6 mm i.d., 15 cm length,
YMC, Japan) were used. UV detector (274 nm) and fluorescence detector (Ex 278nm, Em 305nm) was
used for the purification, absorption experiments, respectively, and a flow rate was 1.5 ml/min. 
RESULTS AND DISCUSSIONT.  Mizuma et al. 38
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The absorption experiment of LE or cellobiose-coupled LE showed that LE did not appear on the serosal
side, but cellobiose-coupled LE appeared (Fig. 1 in our report (1)). Although the elimination clearance of
cellobiose-coupled LE was lower than that of LE (Fig. 2 in our report (1)), cellobiose-coupled LE was
shown to be metabolized. This indicates that cellobiose-coupling stabilized LE against aminopeptidase,
but the stabilization was not complete. In the presence of peptidase inhibitors, the elimination clearances
of LE and cellobiose-coupled LE from the mucosal side were decreased. However, LE did not appear on
the serosal side. Furthermore, the absorption clearance of cellobiose-coupled LE, which is calculated by
normalization with mucosal concentration according to Eq. 8, was increased in the presence of peptidase
inhibitors. On the contrary, these peptidase inhibitors did not increase the absorption clearance of
unmetabolizable compound, phenol red, indicating that the passive transport was not increased by these
inhibitors. Therefore, it was indicated that cellobiose-coupled LE was metabolized not only on the mucosal
(luminal) side but also in the intestinal tissue during absorption process. Thereby, the effect of peptidase
inhibitors on the stability and intestinal absorption was evaluated by the metabolic inhibition model, which
incorporated the metabolic activity in intestinal tissues into the calculation of the absorption clearance (Eq.
1 and Fig. 2).
The relationship of the intestinal absorption and metabolic clearances, which was shown in Fig. 3 of our
report (1), indicated that the higher the metabolic clearance was, the lower the absorption clearance was,
and that the relationship was hyperbolic. The overall transport clearance was 0.654 l/min/cm. This value
was comparable to that (0.653 l/min/cm) of cellobiose-coupled leucine enkephalinamide (16), which is
resistant to the endopeptidases. On the other hand, when the remaining activity was estimated from the
elimination clearance from the mucosal side, the overall transport of CcpLE was much higher (6.95
l/min/cm) than that of CcpLEamide. These values indicate that the metabolic inhibition model can predict
the absorbability. It was also shown that the intestinal absorption of CcpLE can be improved 8 times by
complete inhibition of metabolism according to the Eq. 4.  
The metabolic inhibition model was also applicable to the intestinal absorption of KTP (2). KTP did not
appear on the serosal side. However, in the presence of peptidase inhibitors such as o-phenanthrolin,
tryptophan hydroxamate and bestatin, KTP appeared on the serosal side. Therefore, the metabolic inhibition
model was also applied to the evaluation of the effect of peptidase inhibitors on the improved absorption.
The overall transport clearance of KTP was 0.247 l/min/cm. Meanwhile, the absorption clearance (the
overall transport clearance) of D-KTP, peptidase-resistant isomer of KTP, was 0.516 l/min/cm, and was
approximately similar to that of KTP. This indicates that the metabolic inhibition model approximately
predicts the absorbability of KTP as well, and that the absorption clearance of KTP can be increased by
metabolic inhibition.
On the other hand, no correlation of the absorption clearance with the elimination clearance was observed
in the absorption of KTP and Boc-KTP (Fig. 6a and b in our report (2)). The results with KTP and Boc-
KTP as well as CcpLE indicate that the elimination activity from the mucosal side does not affect the
absorption clearance.
Drug metabolism affect the bioavailability of drug following oral administration, but the contribution of
intestinal metabolism to the bioavailability has not been evaluated. The estimation of two hybrid
parameters is enough for the prediction of the absorbability by the metabolic inhibition model, althoughT.  Mizuma et al. 39
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a number of parameters are incorporated into Eq. 1. Therefore, this model, which predicts the extent of the
contribution of metabolizability to the absorbability, is useful.
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